Compare ISOU & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISOU | LBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Canada | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.3M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | ISOU | LBRX |
|---|---|---|
| Price | $11.81 | $32.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | 89.2K | ★ 267.8K |
| Earning Date | 05-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.94 | $13.40 |
| 52 Week High | $13.58 | $33.47 |
| Indicator | ISOU | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 67.92 |
| Support Level | $9.62 | $21.90 |
| Resistance Level | $11.90 | $33.47 |
| Average True Range (ATR) | 0.72 | 1.75 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 33.64 | 90.78 |
IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Geiger, Thorburn Lake, Full Moon, Edge, Collins Bay Extension, North Thorburn, 2Z Lake, and Madison. It operates in Canada, the United States, and Australia.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.